Brian Jaffe, MD
Critical Care Medicine · Marlton, NJNPI 1346401023
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 236 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AstraZeneca at 29.7% of the total. 2025 is the largest year on record at $1,601, more than ten times the $149 reported in 2019.
Across 236 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Sanofi$288
- Regeneron Healthcare Solutions, Inc.$173
- Boehringer Ingelheim$113
- Philips North America LLC$112
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,995100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 54 | $1,190 |
| GSK | 83 | $1,119 |
| Sanofi | 17 | $288 |
| Regeneron Healthcare Solutions, Inc. | 9 | $173 |
| Boehringer Ingelheim | 7 | $113 |
| Philips North America LLC | 6 | $112 |
| Verona Pharma, Inc. | 5 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $82 |
| United Therapeutics Corporation | 5 | $75 |
| Actelion Pharmaceuticals US, Inc. | 4 | $65 |
| Avadel CNS Pharmaceuticals, LLC | 4 | $64 |
| Amgen | 4 | $59 |
| Genentech USA, Inc. | 3 | $52 |
| Jazz Pharmaceuticals Inc. | 3 | $50 |
| ANI Pharmaceuticals, Inc. | 2 | $49 |
| Baxter Healthcare | 2 | $47 |
| Harmony Biosciences LLC | 3 | $45 |
| Grifols USA, LLC | 2 | $45 |
| Lilly USA, LLC | 2 | $35 |
| Insmed, Inc. | 2 | $33 |
| Mylan Specialty L.p. | 2 | $31 |
| Vapotherm Inc | 1 | $29 |
| Sunovion Pharmaceuticals Inc. | 3 | $28 |
| Soleno Therapeutics, Inc. | 1 | $22 |
| Novartis | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Covis Pharma GmbH | 1 | $19 |
| AbbVie | 1 | $18 |
| Resmed Corp | 1 | $17 |
| Merck | 1 | $14 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,006 in reported general payments places this provider in the 80th percentile of 254 critical care medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 323 | $301,027 |
| Dupixent PenDupilumab | 25 | $92,625 |
| Breo ElliptaFluticasone/Vilanterol | 130 | $75,893 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 84 | $55,450 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $33,299 |
| EliquisApixaban | 23 | $26,676 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 135 | $20,529 |
| Spiriva RespimatTiotropium Bromide | 21 | $13,854 |
| Spiriva HandihalerTiotropium Bromide | 19 | $13,770 |
| Incruse ElliptaUmeclidinium Bromide | 23 | $11,584 |
| Advair HfaFluticasone Propion/Salmeterol | 24 | $9,903 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $9,406 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 208 | $8,260 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $6,234 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,119 | $443,954560 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,190 | $38,58966 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $113 | $23,26040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 254 critical care medicine providers in New Jersey.
Other critical care medicine in Marlton
- Neha VagadiaMarlton$31K
- Syed RiazMarlton$12K
- Aaron CrookshankMarlton$8K
- Emilio MazzaMarlton$7K
- Eric SztejmanMarlton$6K
- Jonathan GalliMarlton$5K
- Rohit MalikMarlton$5K
- Angel RodisMarlton$4K
- Andrew SchiffMarlton$4K
- Roman KrolMarlton$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.